Skip to main content
OpenTrials

Clinical trial condition

Idiopathic Pulmonary Fibrosis

Explore clinical trials studying Idiopathic Pulmonary Fibrosis. Study availability and eligibility vary by location and protocol.

436 public trials 72 recruiting studies
Refine in advanced search Browse all conditions

Idiopathic Pulmonary Fibrosis trial results

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02738801

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Municipal Clinical Hospital # 6 Dnipropetrovsk, Ukraine
  • Kharkov City Clinical Hospital # 13 Kharkiv, Ukraine
  • F.G. Yanovskyy Institute of Phthisiatry and Pulmonology 1 Kiev, Ukraine
  • F.G. Yanovskyy Institute of Phthisiatry and Pulmonology 2 Kiev, Ukraine
View Trial Details
Completed

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01890265

Conditions
Fibrosis, Idiopathic Interstitial Pneumonias, Idiopathic Pulmonary Fibrosis, +6 more
Locations
  • The Kirklin Clinic Birmingham, Alabama, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • UC Davis Medical Center Sacramento, California, United States
  • National Jewish Health Denver, Colorado, United States
View all 42 locations
View Trial Details
Completed

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

NCT03115619

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology Athens, Greece
  • University General Hospital of Athens "Attikon", B' University Pulmonary Clinic Chaïdári, Greece
  • University General Hospital of Heraklio, Pulmonary Clinic Heraklio, Greece
  • University General Hospital of Ioannina Ioannina, Greece
View Trial Details
Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • University of Alabama at Birmingham - Division of Pulmonary, Allergy & Criticial Care Birmingham, Alabama, United States
  • St. Joseph's Hospital and Medical Center - Heart Lung Institute/ Clinical Research Phoenix, Arizona, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
View all 72 locations
View Trial Details

Related conditions